MAGiC Ablation Catheter
Stereotaxis, Inc. · Decision date Jul 31, 2026
What did the FDA approve?
FDA records P240014/S001 as a supplement to PMA P240014, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jul 31, 2026.
FDA approval order statement
approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240014.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Jul 31, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P240014/S001
- Regulatory pathway
- PMA supplement
- Applicant
- Stereotaxis, Inc.
- Product code
- LPB
- Decision code
- APPR
- Decision date
- Jul 31, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Cardiac ablation percutaneous catheter.
- Applicant
- Stereotaxis, Inc.
- Product code
- LPB
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240014. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240014 · Original PMA
MAGiC Ablation Catheter
P240014/S001 received
Application receipt date recorded by FDA.
P240014/S001 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P240014. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240014
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MAGiC Ablation CatheterP240014 | Stereotaxis, Inc. | PMA approval | Jan 5, 2026 | FDA |
Explore the linked device profile
Other records with product code LPB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biosense Webster, Inc. | PMA supplement | Sep 15, 2026 | FDA | |
| Irvine Biomedical, Inc. | PMA supplement | Sep 3, 2026 | FDA | |
Ampere GeneratorP040014/S051 | Irvine Biomedical, Inc. | PMA supplement | Aug 7, 2026 | FDA |
Ampere GeneratorP960016/S094 | St Jude Medical | PMA supplement | Aug 7, 2026 | FDA |
| Medtronic Cryocath, LP | PMA supplement | Apr 23, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Stereotaxis, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 710 Tucker Blvd., Suite 110, Saint Louis, MO, 63101
Sources and methodology
- Original FDA record: P240014/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


